Mostrar el registro sencillo del ítem
| dc.contributor.author | Quiroga, Borja | |
| dc.contributor.author | Ortiz, Alberto | |
| dc.contributor.author | Núñez, Sara | |
| dc.contributor.author | Kislikova, María | |
| dc.contributor.author | González-Sanchidrian, Silvia | |
| dc.contributor.author | Broseta, José-Jesús | |
| dc.contributor.author | Albines, Zoila-Stany | |
| dc.contributor.author | Escamilla-Cabrera, Beatriz | |
| dc.contributor.author | Rivero-Viera, Yaiza | |
| dc.contributor.author | Rodríguez-Santarelli, David-P | |
| dc.contributor.author | Salanova-Villanueva, Laura | |
| dc.contributor.author | López-Rodríguez, Francisca | |
| dc.contributor.author | Cancho-Castellano, Bárbara | |
| dc.contributor.author | Ibáñez-Cerezon, María | |
| dc.contributor.author | Gutiérrez-Rivas, Carmen-Patricia | |
| dc.contributor.author | Areste, Nuria | |
| dc.contributor.author | Campos-Gutiérrez, Belén | |
| dc.contributor.author | Gálvez, Ana-Rodenas | |
| dc.contributor.author | Piza, María-Constanza-Glucksmann | |
| dc.contributor.author | Manzanos, Sagrario-Balda | |
| dc.contributor.author | Soldevila-Orient, Amparo | |
| dc.contributor.author | Gayo, Lucía-Rodríguez | |
| dc.contributor.author | Moral-Berrio, Esperanza | |
| dc.contributor.author | Díaz, Mayra-Ortega | |
| dc.contributor.author | Beltrán-Catalán, Sandra | |
| dc.contributor.author | García, Adriana-Puente | |
| dc.contributor.author | Rojas, Miguel-Ángel | |
| dc.contributor.author | Barrios, RHaridian-Sosa | |
| dc.contributor.author | Santana-Zapatero, Henar | |
| dc.contributor.author | Rangel-Hidalgo, Gema | |
| dc.contributor.author | Martínez-Canet, Ana-María | |
| dc.contributor.author | Díez, Javier | |
| dc.date.accessioned | 2025-11-20T07:12:56Z | |
| dc.date.available | 2025-11-20T07:12:56Z | |
| dc.date.issued | 2024 | |
| dc.identifier.citation | Quiroga B, Ortiz A, Núñez S, Kislikova M, González Sanchidrián S, Broseta JJ, et al. Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study. Cardiorenal Med [Internet]. 3 de abril de 2024 [citado 19 de noviembre de 2025]; Disponible en: https://karger.com/article/doi/10.1159/000538030 | |
| dc.identifier.issn | 1664-3828 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21429 | |
| dc.description.abstract | INTRODUCTION: Chronic heart failure (HF) has high rates of mortality and hospitalization in patients with advanced chronic kidney disease (aCKD). However, randomized clinical trials have systematically excluded aCKD population. We have investigated current HF therapy in patients receiving clinical care in specialized aCKD units. METHODS: The Heart And Kidney Audit (HAKA) was a cross-sectional and retrospective real-world study including outpatients with aCKD and HF from 29 Spanish centers. The objective was to evaluate how the treatment of HF in patients with aCKD complied with the recommendations of the European Society of Cardiology Guidelines for the diagnosis and treatment of HF, especially regarding the foundational drugs: renin-angiotensin system inhibitors (RASi), angiotensin receptor blocker/neprilysin inhibitors (ARNI), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). RESULTS: Among 5,012 aCKD patients, 532 (13%) had a diagnosis of HF. Of them, 20% had reduced ejection fraction (HFrEF), 13% mildly reduced EF (HFmrEF), and 67% preserved EF (HFpEF). Only 9.3% of patients with HFrEF were receiving quadruple therapy with RASi/ARNI, BB, MRA, and SGLT2i, but the majority were not on the maximum recommended doses. None of the patients with HFrEF and CKD G5 received quadruple therapy. Among HFmrEF patients, approximately half and two-thirds were receiving RASi and/or BB, respectively, while less than 15% received ARNI, MRA, or SGLT2i. Less than 10% of patients with HFpEF were receiving SGLT2i. CONCLUSIONS: Under real-world conditions, HF in aCKD patients is sub-optimally treated. Increased awareness of current guidelines and pragmatic trials specifically enrolling these patients represent unmet medical needs. | |
| dc.language.iso | eng | |
| dc.publisher | KARGER | |
| dc.rights | https://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.rights.uri | Atribución/Reconocimiento-NoComercial 4.0 Internacional | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Heart Failure/complications/drug therapy/physiopathology | |
| dc.subject.mesh | Retrospective Studies | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Renal Insufficiency, Chronic/complications/physiopathology | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Cross-Sectional Studies | |
| dc.subject.mesh | Mineralocorticoid Receptor Antagonists/therapeutic use | |
| dc.subject.mesh | Angiotensin Receptor Antagonists/therapeutic use | |
| dc.subject.mesh | Adrenergic beta-Antagonists/therapeutic use | |
| dc.subject.mesh | Sodium-Glucose Transporter 2 Inhibitors/therapeutic use | |
| dc.subject.mesh | Stroke Volume/physiology | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Spain/epidemiology | |
| dc.subject.mesh | Guideline Adherence | |
| dc.subject.mesh | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | |
| dc.subject.mesh | Aged, 80 and over | |
| dc.title | Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 38513622 | |
| dc.relation.publisherversion | https://karger.com/article/doi/10.1159/000538030 | |
| dc.identifier.doi | 10.1159/000538030 | |
| dc.journal.title | Cardiorenal Medicine | |
| dc.identifier.essn | 1664-5502 |